[Level of evidence for therapeutic drug monitoring for docetaxel].
Fiche publication
Date publication
mai 2010
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ROYER Bernard
Tous les auteurs :
Gerritsen-van Schieveen P, Royer B
Lien Pubmed
Résumé
Pharmacokinetic properties of docetaxel, an anticancer drug, are though to be interesting for therapeutic drug monitoring: high inter- and intra-variability, relationship between exposure and efficacy and especially toxicity. Moreover, the 3-weekly administration, which is the more effective scheme, is also the more toxic. However, neutropenia can be modeled and be efficiently predicted without needing plasma drug concentrations. The level evidence of therapeutic drug monitoring is thus weak regarding the possibility to adapt dose regimen without drug concentrations.
Référence
Therapie. 2010 May-Jun;65(3):201-6